Dichloromethane → (E)-3-{4-[2-(4-Methyl-piperazin-1-yl)-2-oxo-ethyl]-2-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-7-yl}acrylic acid hydrochloride
반응식
Br[C:2]1[CH:23]=[N:22][C:5]2[NH:6][C:7](=[O:21])[CH2:8][N:9]([CH2:11][C:12]([N:14]3[CH2:19][CH2:18][N:17]([CH3:20])[CH2:16][CH2:15]3)=[O:13])[CH2:10][C:4]=2[CH:3]=1.[C:24]([O:28]C(C)(C)C)(=[O:27])[CH:25]=[CH2:26].C(N(C(C)C)C(C)C)C.CC1C=CC=CC=1P(C1C=CC=CC=1C)C1C=CC=CC=1C.C(Cl)[Cl:65]>C(#N)CC.CN(C=O)C.CC([O-])=O.CC([O-])=O.[Pd+2]>[ClH:65].[CH3:20][N:17]1[CH2:18][CH2:19][N:14]([C:12](=[O:13])[CH2:11][N:9]2[CH2:10][C:4]3[CH:3]=[C:2](/[CH:26]=[CH:25]/[C:24]([OH:28])=[O:27])[CH:23]=[N:22][C:5]=3[NH:6][C:7](=[O:21])[CH2:8]2)[CH2:15][CH2:16]1참가 물질
반응물 5
생성물 1
시약·촉매·용매 3
실험 절차
A suspension of 7-Bromo-4-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethyl]-1,3,4,5-tetrahydro-pyrido[2,3-e][1,4]diazepin-2-one (1.39 g, 3.64 mmol) in propionitrile (32 mL) and DMF (8 mL) was de-oxygenated with Ar for 15 min. The mixture was treated with tert-butyl acrylate (2.1 mL, 14 mmol) and (i-Pr)2EtN (1.3 mL, 7.4 mmol) and then was de-oxygenated with Ar for 10 min. Pd(OAc)2 (83 mg, 0.37 mmol) and P(o-tol)3 (0.22 g, 0.73 mmol) were added simultaneously, and the mixture was de-oxygenated a third time for 10 min. The mixture was heated to reflux overnight, then allowed to cool. The resulting precipitate was isolated by filtration and dissolved in CH2Cl2. The solution was filtered through Celite and the solvent was removed in vacuo to give the title compound (1.13 g, 72%) as an off-white solid: MS (ESI) m/e 430 (M+H)+.
후처리
- waitwas de-oxygenated with Ar for 10 min
- customfor 10 min
- temperatureThe mixture was heated
- temperatureto reflux overnight
- temperatureto cool
- customThe resulting precipitate was isolated by filtration
- filtrationThe solution was filtered through Celite
- customthe solvent was removed in vacuo
출처 및 근거
- ORD 기록
- ord-88720258b9354494b852440be1d03834
- 출처 데이터셋
- uspto-grants-2010_09
- 특허 번호
- US07790709B2
반응 노트
불러오는 중…